Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03172039
Other study ID # 16-6388
Secondary ID
Status Completed
Phase N/A
First received May 28, 2017
Last updated October 24, 2017
Start date May 12, 2017
Est. completion date September 1, 2017

Study information

Verified date October 2017
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This quality improvement study will assess the antimicrobial use and prescribing practices of hospital and community prescribers for the ambulatory hemodialysis (HD) population in an urban academic outpatient HD unit in Ontario. Currently, in the outpatient HD unit at Toronto General Hospital (TGH), it is the standard of care for the patients to be screened on a weekly basis by the nephrology care team for the use of any oral or intravenous antimicrobials. Patient charts, pharmacy patient profiles and electronic medical records for these patients from September 1 2016 - April 30 2017 will be retrospectively reviewed in order to characterize antimicrobial use and its concordance with available clinical guidelines and antimicrobial stewardship principles described by the Centers for Disease Control and Prevention (CDC). The primary objective of the study is to determine the prevalence of antimicrobial use in an ambulatory HD population. The secondary objective of the study is to determine the congruence of prescribed antimicrobial regimens with available clinical guidelines and antimicrobial stewardship principles described by the CDC. It is hypothesized that antimicrobial use among HD patients will be common and that antimicrobial prescribing practices are not congruent with recommendations from published clinical guidelines and antimicrobial stewardship principles for a significant proportion of patients included in the retrospective review. Descriptive analysis of the data will summarize the findings. Future research will build upon the results of this project, and may include the development of interventions that target gaps in knowledge and prescribing behaviours of prescribers who provide care to the ambulatory HD population.


Description:

Description of Study:

Patients who make up the ambulatory hemodialysis (HD) population at Toronto General Hospital (TGH) are interviewed on a weekly basis about their antimicrobial use during the nursing-led bedside huddle as part of the standard of care. These huddles take place daily during each of the four HD shifts: morning, afternoon, evening and nocturnal. During the huddle the nurse or patient care coordinator asks the patient if they have been prescribed an oral or intravenous antimicrobial by a hospital or community prescriber in the past 7 days. A Best Possible Medication History (BPMH) is completed by a HD Pharmacy team member for all patients who stated they have started a new antimicrobial. A BPMH is a patient's medication history which is defined as "a systematic process of interviewing the patient/family", and "a review of at least one other reliable source of information" (e.g., dispensing pharmacy records, hospital discharge records etc.) to confirm medication use. The BPMH is part of routine care in the HD unit and obtained at regular intervals (e.g., when a medication is started, changed or discontinued) to ensure the most accurate medication history is available. The BPMH containing information about the antimicrobial treatment is documented in the patient's medical chart, as well as in the electronic pharmacy patient profile. There will be no disruption to the current pharmacy practice and workflow in the HD unit by this study.

At the end of the data collection period, a panel compromising of a pharmacy resident, antimicrobial stewardship pharmacist, nephrology pharmacist, nurse practitioner and nephrologist will adjudicate each antimicrobial prescription with a presumed indication for congruence with available clinical guidelines and antimicrobial principles described by CDC. Each antimicrobial regimen will be categorized as congruent or non-congruent; any regimen for which there is inadequate or unavailable documentation in support of congruence will be classified as unknown congruence. The primary tool for assessing antimicrobial therapy will be against antimicrobial stewardship best practices guiding principles established by CDC, supplemented by applicable guidelines for each site of suspected infection published by major infectious disease and nephrology societies. Evidence-based resources for drug dosing in renal failure will be used to determine whether the prescribed antimicrobial regimen is consistent with literature-based dosing recommendations. The prescription will be assessed for types of stewardship-discordant prescribing that will be defined based on general stewardship principles a priori such as the following:

i) antimicrobial regimen has incorrect dose/route/frequency for intended infectious syndrome, pathogens and/or patient factors ii) length of treatment too short (discontinuation before adequate source control or clinical stability) or too long (prolonged therapy despite documented microbiologic clearance or resolution of symptoms) iii) empiric therapy spectrum too broad or narrow considering possible causative pathogens iv) antimicrobial therapy not tailored/streamlined/de-escalated for microbiology results v) non-infectious syndrome

Number of subjects:

The outpatient HD unit at TGH has a typical census of 300 patients. It is estimated that approximately 300 patient charts will be identified for inclusion as this study will be a non-comparative analysis of all patients admitted to the HD unit.

Statistics:

Data will be tabulated and analyzed using Microsoft Excel software. Descriptive statistics will be used to analyze the data. Means and standard deviations, as well as counts and proportions will be calculated for baseline parameters and relevant endpoints as appropriate. No interim analyses of the data are anticipated.

Procedure for accounting for missing, unused, and spurious data:

A patient's medical chart and pharmacy patient profile are comprehensive for obtaining a patient's medication history and therefore missing data should not be a concern. If this issue arises all available data sources will be exhausted (e.g., electronic patient record, pharmacy patient profiles).

Quality Assurance:

All data will be collected by the designated study team member using a data collection sheet and following a systematic approach approved by the project team. Raw data will be validated and reviewed by the project team following the completion of data collection and prior to data analysis.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date September 1, 2017
Est. primary completion date September 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age

- Receiving outpatient hemodialysis (HD) for at least 3 months

- Prescribed at least one oral or intravenous antimicrobial (antibacterial or antifungal or antiviral) by a hospital or community prescriber between September 2016 to April 30 2017 inclusive

Exclusion Criteria:

- In-patients admitted to hospital

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Toronto General Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of antimicrobial prescriptions in an ambulatory hemodialysis population Prevalence will be determined by the total number of antimicrobial prescriptions in the study population over the period of study. An antimicrobial prescription will be defined as any oral or intravenous antibacterial or antifungal or antiviral agent prescribed by a community or hospital prescriber to a patient receiving hemodialysis (HD) from Toronto General Hospital's outpatient HD unit. An antimicrobial prescription will follow the 21-day rule.The 21-day rule is that there must be 21 or more days from the end of one antimicrobial course to the beginning of a second antimicrobial course for two courses to be reported as separate prescriptions. If antimicrobials are stopped for fewer than 21 days and then restarted, the second start is not considered a new prescription, and therefore will not be reported. September 1 2016 - April 30 2017
Secondary Congruence of prescribed antimicrobial regimens Proportion of antimicrobial prescriptions congruent with available clinical guidelines and antimicrobial stewardship principles based on:
i) indication ii) antimicrobial agent iii) spectrum of activity against most likely causative pathogen iv) dose v) route of administration vi) dosing frequency vii) length of treatment
September 1 2016 - April 30 2017
See also
  Status Clinical Trial Phase
Recruiting NCT05846399 - CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) Phase 4
Recruiting NCT05904535 - Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
Not yet recruiting NCT04075344 - Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs N/A
Completed NCT05333133 - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children N/A
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Recruiting NCT06283433 - A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT N/A
Recruiting NCT06178822 - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed NCT03688321 - Probiotic on Prevention of GBS Vaginal Infection During Pregnancy N/A
Completed NCT03244917 - Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias N/A
Recruiting NCT04450680 - Beta-lactam Therapeutic Drug Monitoring in Singapore
Completed NCT05686577 - How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care
Recruiting NCT06093269 - Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL) Phase 4
Recruiting NCT05587283 - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women Phase 1
Recruiting NCT03752424 - Topical Silver Nanoparticles for Microbial Activity Phase 1
Completed NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Active, not recruiting NCT05150015 - ElastoMeric Infusion Pumps for Hospital AntibioTICs N/A
Completed NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Terminated NCT03555981 - Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates N/A
Completed NCT03133312 - Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery Phase 4
Recruiting NCT04800575 - Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter N/A